Prostate Cancer Prognosis and Risk Stratification

EP: 1.Incidence and Risk Factors of Prostate Cancer

EP: 2.Presentation and Diagnosis of Prostate Cancer

EP: 3.Screening and Diagnosis of Prostate Cancer

Now Viewing

EP: 4.Prostate Cancer Prognosis and Risk Stratification

EP: 5.Differences in the Treatment of Patients with Prostate Cancer

EP: 6.Prostate Cancer: Treatment Decision-Making and the Role of Guidelines

EP: 7.Informing Prostate Cancer Treatment Decisions with Clinical Trials and Real-World Evidence

EP: 8.Systemic Therapy for Prostate Cancer

EP: 9.Androgen Deprivation Therapy for Prostate Cancer

EP: 10.Metastatic Hormone-Sensitive Prostate Cancer Treatment Options

EP: 11.Overview of Castrate-Resistant Prostate Cancer (CRPC)

EP: 12.Treatment Options for Nonmetastatic CRPC

EP: 13.Treatment Approach for Patients With Metastatic CRPC

EP: 14.The Role of Combination Therapy in mCRPC

EP: 15.Improving Clinical Trials in Prostate Cancer

EP: 16.Educating Patients and Caregivers About Prostate Cancer

EP: 17.Advice for Patients With Prostate Cancer

This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.

In this transcript, Rashid K. Sayyid, MD, MSc, a urologic oncology fellow at the University of Toronto, offers insights on prostate cancer. He first discusses disease staging, categorizing prostate cancer into localized, locally advanced, and metastatic disease. Dr Sayyid notes treatment implications and prognosis by stage, stating localized and locally advanced disease generally have good 10-year prognosis while metastatic disease ranges from 3-8 years depending on extent of metastases.

Dr Sayyid then addresses risk stratification, stating the National Comprehensive Cancer Network (NCCN) classification system categorizes patients from very low to high risk, impacting treatment decisions. This classification uses variables like Gleason score, prostate-specific antigen (PSA) level, clinical stage, biopsy positivity percentage, and imaging findings.

In summarizing key points, Dr. Rashid K. Sayyid covers disease staging, prognosis, risk classification, and treatment implications for prostate cancer patients. He highlights emerging treatments improving prognosis, especially for metastatic disease.

*Video synopsis is AI-generated and reviewed by CURE editorial staff.